5 research outputs found

    Antioxidant and antimicrobial activity in the seeds of Origanum vulgare L. subsp. gracile (C. Koch) Ietswaart and Origanum acutidens (Hand.-Mazz.) Ietswaart from Turkey.

    Get PDF
    The present study determined some biological compounds (fatty acids, vitamins, sterols and flavonoids), radical scavenging capacity and antimicrobial activity of two Origanum L. species of Origanum vulgare L. subsp. gracile (C. Koch) Ietswaart and Origanum acutidens (Hand.-Mazz.). Ietswaart. Linolenic acid was found to be the main fatty acid in both species, which was followed by palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:1 n9), linoleic acid (C18:2 n6) and stearidonic acid (C18:4). In addition, the two Origanum species were recorded as containing high levels of stigmasterol. It was also found that Origanum vulgare L. subsp. gracile (C. Koch) Ietswaart had a high β-sitosterol content (152.82.6 µg/g); high amounts of D3 (33.10.8 µg/g), K1 (29.40.8 µg/g), K2 (26.00.8 µg/g) vitamins; and low amounts of α-tocopherol (7.80.2 µg/g) and D2 (1.80.1 µg/g), while Origanum acutidens (Hand.-Mazz.) Ietswaart contained high amounts of D2 (42.91.5 µg/g) vitamin; and low amounts of D3 (2.90.1 µg/g), α-tocopherol (3.10.1 µg/g), r-tocopherol (3.50.2 µg/g), K2 (1.30.1 µg/g), retinol (1.30.2 µg/g) and retinol acetate (1.20.1 µg/g) vitamins. The present study showed that Origanum vulgare L. subsp. gracile (C. Koch) Ietswaart and Origanum acutidens (Hand.-Mazz.) Ietswaart contained the lowest amount of flavonoid. Furthermore, methanol extracts were recorded to be the most effective agent against the DPPH radical in both Origanum L. species examined. Experimental results showed that the vitamins, flavonoids and fatty acid extracts of both Origanum L. species were effective in the inhibition of thegrowth of the tested microorganisms at varying levels

    Moroccan antidiabetic medicinal plants: Ethnobotanical studies, phytochemical bioactive compounds, preclinical investigations, toxicological validations and clinical evidences; challenges, guidance and perspectives for future management of diabetes worldwide

    No full text
    corecore